1. What counts as a silent ASCVD event

Eight entities are routinely conflated. They have different denominators, different ascertainment methods, and different implications, and their statistics must not be pooled.

श्रेणी	परिभाषा	What it is not
शांत मायोकार्डियल इंफार्क्शनपूर्ण प्रविष्टि के लिए हार्ट अटैक देखें।.	Objective evidence of prior infarction — pathological Q wavesAbnormal deflections on an electrocardiogram that indicate an area of electrically inactive (scarred or dead) heart muscle from a prior myocardial infarction. The Fourth and Fifth Universal Definitions of Myocardial Infarction use their presence, in the absence of non-ischemic causes, as one criterion for diagnosing a prior or silent infarction., or myocardial scar on imaging — not recognized when it occurred [2].	Not a claim about what the person felt. It is a claim about what was diagnosed.
Unrecognized myocardial infarction	Umbrella term covering both truly asymptomatic events and events with mild, atypical or misinterpreted symptoms [6].	Not interchangeable with asymptomatic. This review uses unrecognized wherever the evidence is diagnostic.
Silent myocardial ischaemia	Transient supply–demand mismatch without एनजाइनाएंजाइना सीने की वह बेचैनी है जो तब होती है जब हृदय की मांसपेशियों को पर्याप्त ऑक्सीजन नहीं मिल रही होती है। लोग इसे दबाव, जकड़न, कसाव या जलन के रूप में वर्णित करते हैं, और यह हाथ, गर्दन या जबड़े तक फैल सकता है।., reversible, demonstrable on ambulatory or stress testing.	Not an infarction. A positive तनाव परीक्षणA stress test watches your heart while you exercise on a treadmill or bike, sometimes with imaging added. is not a count of previous दिल के दौरेहार्ट अटैक तब होता है जब हृदय की मांसपेशियों के एक हिस्से में रक्त का प्रवाह रुक जाता है और वह मांसपेशी मरने लगती है।..
अचानक हृदय गति बंद होने से मौतअचानक कार्डियक डेथ वह स्थिति है जब दिल अचानक धड़कना बंद कर देता है और व्यक्ति की कुछ ही मिनटों में मौत हो जाती है, अक्सर बिना किसी पूर्व चेतावनी के।. as first manifestation	Fatal arrest in a person with no previously recognized cardiovascular diagnosis [19].	An outcome, not a synonym for infarction. It may arise from an old scar, हृदय पेशी रोगCardiomyopathy is disease of the heart muscle itself, rather than of the arteries feeding it., or a primary electrical disorder.
Silent (covert) cerebral infarction	Brain infarction on MRI or CT without a previously diagnosed clinical आघातस्ट्रोक तब होता है जब मस्तिष्क के किसी हिस्से में रक्त का प्रवाह रुक जाता है, जो या तो किसी रुकावट के कारण होता है या खून बहने के कारण।. [4].	Not white matter hyperintensity, not an enlarged perivascular space, not a microbleed. Those are separate markers [26].
Unrecognized or minimally symptomatic stroke	Brain infarction that did produce symptoms — brief imbalance, transient visual change — not attributed to stroke [4].	Distinct from a covert infarct found incidentally. Here symptoms occurred but were misread.
Asymptomatic धमनी काठिन्यएथेरोस्क्लेरोसिस वह बीमारी है जो अधिकांश दिल के दौरों और कई स्ट्रोक के पीछे होती है। कोलेस्ट्रॉल के कण धमनी की दीवार में फंस जाते हैं, शरीर उन्हें साफ करने के लिए प्रतिरक्षा कोशिकाओं को भेजता है, और वर्षों में वह मलबा पट्टिका (प्लाक) के रूप में सख्त हो जाता है।.	Coronary calcium, carotid पट्टिकाप्लाक धमनी की दीवार के अंदर कोलेस्ट्रॉल, प्रतिरक्षा कोशिकाओं, निशान ऊतक और कैल्शियम का निर्माण है।., aortic plaque, or reduced ankle-brachial index found before any clinical event [30].	NOT a silent event. Plaque is a risk marker. Classifying it as an event inflates every downstream statistic.
Silent peripheral arterial disease	Ankle-brachial index at or below 0.90 without claudication [31].	Not an acute event. Chronic subclinical disease, prognostically important, but not something that happened on a date.

Definitions follow the Universal Definitions of Myocardial Infarction [2,3] and the AHA/ASA statement on covert मस्तिष्कवाहिनी रोगमस्तिष्क को रक्त की आपूर्ति करने वाली रक्त वाहिकाओं को प्रभावित करने वाला रोग, जिसमें स्ट्रोक भी शामिल है; मेटा-विश्लेषणों की एक छत्र समीक्षा में शाकाहारी और वीगन आहार द्वारा कम किए जाने वाले परिणाम के रूप में हृदय रोग के साथ इसका उल्लेख किया गया है।. [4].

The Fourth Universal Definition states that prior or silent infarction may be diagnosed by abnormal Q waves with or without symptoms in the absence of non-ischaemic causes, by imaging evidence of loss of viable myocardiumThe myocardium is the muscular wall of the heart — the part that actually squeezes to push blood around your body. in an ischaemic pattern, or by pathoanatomical findings [2]. The Fifth Universal Definition, published in 2026, adds that pathological Q waves have limited specificity and should where possible be confirmed by imaging, preferably cardiac magnetic resonance with late gadolinium enhancementLate gadolinium enhancement (LGE) is a cardiac MRI technique in which a contrast agent accumulates in areas of scarred or fibrotic myocardium and appears bright on delayed imaging, indicating previous microscopic or clinical cardiac injury; 12–14% of masters athletes in the studies described showed this pattern, sometimes without any prior diagnosed heart attack., and cautions that the term silent can in some cases be misleading [3].

On the cerebral side, the AHA/ASA statement recognises three cardinal manifestations — silent brain infarcts, white matter hyperintensities of presumed vascular origin, and cerebral microbleedsSmall deposits of hemosiderin in brain tissue visible as dark spots on susceptibility-weighted MRI sequences, indicating prior minor hemorrhage from small-vessel disease; they are a separate finding from covert brain infarcts and white matter hyperintensities. — and prefers covert to silent [4]. A further caution belongs in any ASCVD review: not every covert brain infarct is atherosclerotic. Some arise from large-artery disease, others from अलिफ़ल कम्पनएट्रियल फाइब्रिलेशन, जिसे अक्सर एफ़िब (AFib) कहा जाता है, एक तेज़ और अनियमित दिल की धड़कन है जो दिल के ऊपरी कक्षों से शुरू होती है।. or another embolic source, and many deep घावहृदय रोग विज्ञान में, एक घाव (लेशन्) एथेरोस्क्लेरोटिक प्लाक के एक अलग क्षेत्र को संदर्भित करता है जो कोरोनरी धमनी को सिकोड़ता है, जिसे आमतौर पर इसके कारण होने वाले लुमिनल अवरोध के प्रतिशत से वर्णित किया जाता है। लेख चार ऐसे अवशिष्ट घावों का वर्णन करता है जो सबसे महत्वपूर्ण का इलाज किए जाने के बाद स्टेंट स्वीकार करने के लिए पोत के व्यास में बहुत छोटे हैं।. from small-vessel disease [4,5]. The vascular burden is broader than the specifically atherosclerotic burden.

2. How many occur in the United States

The AHA Heart Disease and Stroke Statistics Update reports 371,506 U.S. deaths from कोरोनरी हृदय रोगकोरोनरी हृदय रोग हृदय की मांसपेशी को रक्त की आपूर्ति करने वाली धमनियों का संकुचन या अवरोध है, जो एथेरोस्क्लेरोटिक प्लाक के जमा होने के कारण होता है; यह दुनिया भर में दिल के दौरे और कार्डियक मौत का प्रमुख कारण है।. in 2022 and 165,393 from stroke. Based on surveillance from 2005 to 2014, it estimates roughly 605,000 new and 200,000 recurrent myocardial infarctions annually, with average age at first infarction of 65.6 years in men and 72.0 years in women [1]. U.S. stroke incidence is conventionally cited as approximately 795,000 per year, about 87% ischaemic [1].

Two cautions. These rest on a surveillance window that closed more than a decade ago, and they count clinically recognized events. Public summaries describing about one in five heart attacks as silent are arithmetic applied to those rounded totals, not independently measured national subgroup counts, and they carry no विश्वास अंतरालविश्वास अंतराल उन मान्यों की वह श्रेणी है जो किसी अध्ययन में प्राप्त परिणामों के साथ सांख्यिकीय रूप से संगत होती है।..

Cohort data give a different and better-characterised picture. In एआरआईसीARIC, the Atherosclerosis Risk in Communities study, has followed thousands of American adults since the late 1980s., among 9,498 participants initially free of हृदय रोगहृदय वाहिनी रोग हृदय और रक्त वाहिकाओं से जुड़ी समस्याओं के लिए एक व्यापक शब्द है, जिसमें दिल का दौरा, स्ट्रोक और पैर की धमनियों का अवरुद्ध होना शामिल है।., investigators detected 317 ECG-defined unrecognized and 386 clinically documented infarctions over a median 8.9 years — 45.1% of detected incident infarctions were unrecognized [8]. In Framingham, more than 25% of 708 infarctions among 5,127 participants were discovered only through routine biennial electrocardiography [6]. In MESAमेसा (MESA), यानी मल्टी-एथनिक स्टडी ऑफ़ एथेरोस्क्लरोसिस, ने दिल की किसी भी ज्ञात बीमारी से रहित हज़ारों वयस्कों का अनुसरण किया, उनकी धमनियों की स्कैनिंग की और परिणामों पर नज़र रखी।., हृदय एमआरआईकार्डियक एमआरआई (Cardiac MRI) हृदय की सूक्ष्म छवियों को लेने के लिए एक्स-रे के बजाय चुंबकीय क्षेत्रों (magnetic fields) का उपयोग करता है, जिसमें कोई विकिरण (radiation) नहीं होता है।. found myocardial scar in 146 of 1,840 participants, of which 114 had not been identified by ECG or clinical न्यायनिर्णयऐजुडिकेशन (निर्णयन) वह प्रक्रिया है जिसमें एक स्वतंत्र समिति परीक्षण में रिपोर्ट की गई प्रत्येक घटना की समीक्षा करती है और यह तय करती है कि वास्तव में क्या हुआ था, बिना यह जाने कि रोगी को कौन सा उपचार मिला था।. [11] — though that study included both ischaemic and non-ischaemic scar patterns, so its frequently quoted unrecognized share is a percentage of scars, not of heart attacks.

Applying any of these cohort proportions to the national total would combine different definitions, eras, and age structures. The defensible statement is that U.S. silent infarctions number in the hundreds of thousands annually and that no validated national count exists.

2.1 Sudden cardiac death

Sudden cardiac death accounts for approximately half of cardiovascular deaths, and coronary disease underlies the majority [19]. The Finnish Fingesture studyA Finnish autopsy-based series of 5,869 consecutive sudden cardiac deaths between 1998 and 2017; among coronary-disease deaths in people with no prior cardiovascular diagnosis, 42.4% had myocardial scarring indicating a previous silent infarction. provides the clearest quantification: among 5,869 consecutive autopsy-verified sudden cardiac deaths between 1998 and 2017, 4,392 were attributed to कोरोनरी धमनी रोगकोरोनरी धमनी रोग (कोरोनरी आर्टरी डिज़ीज़) हृदय की मांसपेशी को रक्त पहुँचाने वाली धमनियों में प्लाक का जमाव है।.; of those, 3,122 occurred in people with no previously diagnosed coronary disease; and of those 3,122, 1,322 (42.4%) had myocardial scarring indicating a previous silent infarction. Among the subset with an ECG recorded before death, 67% had abnormal findings [19].

Two interpretive limits. This is the probability of finding an old infarct among people who died suddenly, not the probability that a living person with a silent infarct will die suddenly. And a single-country autopsy series is not a U.S. or global estimate.

Nor does first recognized presentation mean no prior symptoms. In an Oregon study of 839 people aged 35 to 65 who suffered हार्ट अटैकCardiac arrest is when the heart suddenly stops pumping and the person collapses, stops breathing normally, and loses consciousness within seconds. and had symptom data available, 51% had warning symptoms in the preceding four weeks, most commonly chest discomfort or breathlessness [20]. Recall bias and incomplete symptom data apply.

Figure 5. Fingesture autopsy series [19]. Percentages are of the preceding bar, not of the total.

3. How many occur worldwide

Every global figure here is modeled. Global Burden of Disease 2021 estimated 11.9 million incident strokes worldwide (95% uncertainty interval 10.7–13.2 million), including 7.8 million ischaemic strokes (6.7–8.9 million) [29]. These describe clinical stroke burden; they are not a census of incidental MRI lesions.

No globally representative surveillance system supplies annual counts of unrecognized infarction confirmed by standardised cardiac MRI, nor of completely symptom-free infarctions. Regional cohorts — Icelandic, Dutch, American, Scandinavian — demonstrate that the problem exists internationally. They do not establish a world total. Population-level neuroimaging and cardiac MRI registries are largely absent from low- and middle-income countries, where most cardiovascular deaths occur.

Two rules this review does not break Silent myocardial infarctions and silent brain infarctions are never added together. They are different diseases, ascertained by different modalities, in different denominators, with different natural histories. No worldwide count of silent events is produced. Applying regional imaging prevalences to the world population would be an extrapolation layered on an extrapolation. Figures of that kind circulate widely; none that this review could trace rests on peer-reviewed global data.

Table 1. Silent and unrecognized myocardial infarction

Estimate	Population / dates	पद्धति	Value	Numerator / denominator	Limitations
Unrecognized share of incident MI	Framingham, U.S., publication 1984 [6]	Biennial serial ECG	>25% of MIs unrecognized	708 MIs among 5,127 participants	Historical diagnostic era; ECG-based; higher share in women (35%) than men (28%) [7]
Truly silent share	Framingham, as above [6]	Serial ECG plus symptom interview	Almost half of unrecognized MIs were silent; remainder atypical	Of the >25% unrecognized	The only direct measurement of the three-way split. 1984 data; recall-dependent; must not be applied to modern percentages
Silent share of incident MI	ARIC, U.S., median 8.9 y follow-up [8]	धारावाहिक 12-लीड ईसीजीएक मानक इलेक्ट्रोकार्डियोग्राम जो हृदय की विद्युत गतिविधि को एक साथ बारह इलेक्ट्रोड स्थितियों से रिकॉर्ड करता है, जो अंगों और छाती पर रखी जाती हैं; जब इसे अधिकतम व्यायाम के दौरान किया जाता है, तो यह इस्कीमिक परिवर्तन — जैसे कि एसटी-सेगमेंट अवसाद — प्रकट कर सकता है, जो विश्राम की स्थिति में अदृश्य होते हैं।., Minnesota codingA standardized system for classifying and scoring electrocardiographic findings—particularly Q waves, ST changes, and T-wave abnormalities—used in epidemiological studies to identify silent or unrecognized myocardial infarction from ECG tracings. In ARIC, different Minnesota Code criteria changed the estimated prevalence of ECG-defined silent infarction more than tenfold.	45.1%	317 of 703 detected incident MIs	ECG-based, so a floor; misses non-Q-wave infarction; surveillance from 1987–1998
ECG-defined prevalence range	ARIC, U.S. [8]	ECG, varying criteria	0.6% to 7.0%	Varies by criterion	The criterion chosen changes the answer more than tenfold
Unrecognized MI prevalence	ICELAND MI, ages 67–93, scanned 2004–2007 [9]	Cardiac MRI, late gadolinium enhancement	17% (95% CI 14–19%)	157 of 936	Elderly, ethnically homogeneous cohort; prevalence not incidence
Same people, ECG only	ICELAND MI [9]	Electrocardiogramइलेक्ट्रोकार्डियोग्राम — ईसीजी या ईकेजी — आपकी त्वचा पर लगाए गए स्टिकर के माध्यम से आपके दिल की विद्युत गतिविधि को रिकॉर्ड करता है। इसमें लगभग एक मिनट लगता है और यह दर्द रहित होता है।.	5% (95% CI 4–6%)	46 of 936	Same participants as the row above; the contrast is the finding
Recognized MI prevalence	ICELAND MI [9,10]	Clinical history and record review	9.7%	91 of 935	Depends on prior healthcare access
Unrecognized share of all MIs	ICELAND MI [9,10]	Cardiac MRI vs clinical record	63%	156 of 247 detected MIs	Cohort is elderly; share expected lower at younger ages
Unrecognized MI in मधुमेहमधुमेह एक ऐसी स्थिति है जिसमें रक्त शर्करा बहुत अधिक बनी रहती है, या तो इसलिए कि शरीर बहुत कम इंसुलिन बनाता है या इसलिए कि यह अपने द्वारा बनाए जाने वाले इंसुलिन का जवाब देना बंद कर देता है।.	ICELAND MI diabetic subgroup [9]	Cardiac MRI	21%	Subgroup of 936	Subgroup analysis; no published CI
Myocardial scar prevalence	MESA, U.S., CMR 2010–2012, mean age 68 [11]	Cardiac MRI	Any scar 146/1,840 (7.9%); previously unrecognized 114/1,840 (6.2%)	As stated	Includes ischaemic AND non-ischaemic scar patterns; the unrecognized share is a share of scars, not of heart attacks
Recognized MI incidence, U.S.	U.S., surveillance 2005–2014 [1]	Clinical ascertainment	~605,000 new, ~200,000 recurrent per year	National estimate	Surveillance window predates the report; counts only diagnosed events; no CI supplied
Worldwide silent MI count	—	—	NOT ESTIMATED	—	No representative global surveillance. Deliberately omitted rather than extrapolated

4. How many people have absolutely no symptoms

Three groups need separating: those who experienced nothing; those with mild or atypical symptoms that were misinterpreted; and those with recognisable symptoms that nonetheless did not produce a diagnosis. Most epidemiological studies do not measure all three reliably and separately.

The Framingham evidence remains the most informative direct measurement. More than a quarter of 708 infarctions were unrecognized; of those, almost half were described as silent and the remainder caused atypical symptoms [6]. The unrecognized proportion was higher in women (35%) than men (28%) [7]. This establishes that truly unnoticed events exist and gives an order of magnitude for their frequency in that cohort.

It does not license taking half of a modern percentage to manufacture a current symptom-free estimate. The diagnostic era, interview methods, and population all differ. Retrospective recall is an intrinsic limitation in both directions: people forget brief illnesses and normalise fatigue, but they also reinterpret old symptoms after seeing a scan, and non-specific symptoms are common in people with no infarct at all.

Modern presentation data address the question from another angle. Among 1,143,513 patients with confirmed myocardial infarction in the National Registry of Myocardial Infarction, 35.4% presented without chest pain — 42.0% of women versus 30.7% of men — and younger women without chest pain had the highest in-hospital mortality [17]. All of these patients reached hospital, so this is strong evidence about the atypical-symptom group and weak evidence about the truly silent group.

Why the word matters Asymptomatic is a claim about a person’s experience. Unrecognized is a claim about the medical record. Nearly all published figures measure the second and are reported as though they measured the first.

Figure 1. Panel A: ascertainment method determines the silent fraction [6,8,9,17]. Panel B: the three-way split as measured in Framingham [6].

5. Symptoms that are commonly overlooked

Ischaemic discomfort may present as pressure, heaviness, tightness, or burning, and may be located in the arm, shoulder, jaw, back, or upper abdomen rather than the chest. Breathlessness and unusual fatigue can be anginal equivalents. Nausea, sweating, light-headedness, or faintness may accompany an episode. A new or reproducible decline in exercise tolerance warrants evaluation, though it is not diagnostic — infection, anaemia, lung disease, and medication effects produce similar changes.

Two calibrations matter. First, chest discomfort remains the most common presenting symptom of तीव्र कोरोनरी सिंड्रोमएक्यूट कोरोनरी सिंड्रोम (ACS) हृदय में रक्त प्रवाह में किसी भी अचानक आई गिरावट — अस्थिर एनजाइना से लेकर पूर्ण दिल के दौरे तक — के लिए इस्तेमाल होने वाला एक व्यापक शब्द है, जो किसी प्लाक के अचानक फटने या कटने-छिलने के कारण होता है।. in both sexes, and absence of chest pain should not be portrayed as the usual female presentation [18]. What the registry data show is a difference in proportion, not a उलटफेरREVERSAL अध्ययन ने कोरोनरी प्लाक (धमनियों में वसा का जमाव) पर क्या प्रभाव पड़ा, यह मापने के लिए इंट्रावास्कुलर अल्ट्रासाउंड का उपयोग करके मध्यम और गहन स्टेटिन थेरेपी की तुलना की।. of the typical picture [17]. Second, current chest-pain guidance discourages using the word atypical as shorthand for harmless [18]; it describes terminology used in older studies, not a category of benign symptoms.

For the brain, abrupt facial or limb weakness, unilateral numbness, language difficulty, visual loss, or a new severe balance disturbance may indicate stroke even when brief or mild [4,44]. Gradual forgetfulness alone does not establish that a silent stroke occurred; clinical assessment connects the timing and pattern of symptoms with imaging.

Symptom	How it typically presents	Why it gets dismissed
Unexplained fatigue or weakness	Tiredness disproportionate to activity, sometimes for days beforehand	Attributed to overwork, poor sleep, ageing, or a virus
Shortness of breath	Breathlessness on exertion or at rest, without chest pain	Attributed to deconditioning, weight, asthma, or anxiety
Nausea, indigestion, upper abdominal discomfort	Epigastric burning or fullness, sometimes with belching	Treated as reflux; antacids taken and the episode passes
Sweating	Cold, clammy perspiration without exertion or heat	Attributed to anxiety, रजोनिवृत्तिMenopause is when a woman's periods stop permanently, usually around age 51, as estrogen levels fall., or infection
Dizziness or faintness	Light-headedness, near-syncope, unsteadiness	Attributed to dehydration, standing too fast, or medication
Jaw, back, shoulder or arm discomfort	Aching or pressure with no chest component	Attributed to musculoskeletal strain or dental problems
Decline in व्यायाम क्षमताव्यायाम क्षमता किसी व्यक्ति द्वारा किए जा सकने वाले अधिकतम शारीरिक कार्य का एक मात्रात्मक माप है, जिसका मूल्यांकन आमतौर पर ग्रेडेड स्ट्रेस टेस्ट के दौरान वॉट में चरम कार्यभार, चरम ऑक्सीजन खपत (VO2 max), या चयापचय समतुल्य (METs) के रूप में किया जाता है। लेख में, स्टेंट लगाने के चार महीने बाद व्यायाम क्षमता में गिरावट से यह संकेत मिला कि केवल इस प्रक्रिया से अंतर्निहित बीमारी ठीक नहीं हुई थी।.	A previously routine effort becomes hard, then recovers	Attributed to a bad day, illness, or ageing — particularly by fit people

6. Who is most vulnerable

A distinction that changes the interpretation For several groups the evidence cannot separate two very different explanations: that the group truly experiences more silent events, or that its events are simply less likely to be diagnosed. The first is a finding about symptom perception. The second is a finding about healthcare delivery. Where the literature cannot distinguish them, this review says so rather than choosing.

6.1 Reasonably consistent evidence

• Older age — the strongest and most consistent association for both silent myocardial infarction and covert brain infarction [9,21,24,27].
• Diabetes — cardiac-MRI-detected unrecognized infarction reached 21% in the ICELAND MI diabetic subgroup against 17% overall [9]. Cardiac autonomic neuropathy is a plausible mechanism; UKPDS examined prognosis of silent infarction in newly diagnosed type 2 diabetes [54]. Neither diagnosis proves an event will be symptom-free.
• Chronic kidney diseaseक्रोनिक किडनी डिजीज गुर्दों की खून से अपशिष्ट पदार्थों को फ़िल्टर करने की क्षमता में एक स्थायी कमी है।. — raises cardiovascular risk and complicates interpretation of chronically elevated troponinTroponin is a protein that leaks into the blood when heart muscle is damaged. A blood test for it is how heart attacks are confirmed. [33,34].
• उच्च रक्तचापहाइपरटेंशन उच्च रक्तचाप के लिए चिकित्सीय शब्द है।. — particularly prominent in covert cerebral disease [21,26].
• धूम्रपानधूम्रपान आपकी रक्त वाहिकाओं की परत को नुकसान पहुँचाता है, रक्तचाप बढ़ाता है, रक्त को अधिक आसानी से थक्का बनाता है, और पट्टिका (प्लाक) के विकास को तेज़ करता है।., मोपापनमोटपा का अर्थ स्वास्थ्य को प्रभावित करने के लिए पर्याप्त मात्रा में अतिरिक्त शरीर की चर्बी होना है।., मेटाबोलिक सिंड्रोममेटाबोलिक सिंड्रोम पांच समस्याओं का एक समूह है जो एक साथ होने की प्रवृत्ति रखते हैं: बड़ा कमर घेरा, उच्च ट्राइग्लिसराइड्स, कम एचडीएल, उच्च रक्तचाप और उच्च रक्त शर्करा। इनमें से तीन या अधिक का होना।., and existing coronary, carotid or peripheral atherosclerosis — established drivers of events generally [30,31,32].
• ऊँचा एलडीएल कोलेस्ट्रॉलLDL कोलेस्ट्रॉल, या LDL-C, वह मात्रा है जो आपके LDL कणों के अंदर होती है। यह लगभग हर मानक लैब रिपोर्ट में दिया जाने वाला नंबर होता है।., एपोलिपोप्राटीनएपolipoprotein रक्त में वसा ले जाने वाले कण से जुड़ी एक प्रोटीन है। वसा और पानी आपस में मिलते नहीं हैं, इसलिए ये प्रोटीन एक आवरण की तरह काम करते हैं जो वसा को रक्तप्रवाह में सुरक्षित रूप से यात्रा करने की अनुमति देता है।. बी, और लाइपोप्रोटीन (ए)लाइपोप्रोटीन (a), जिसे Lp(a) लिखा जाता है और "एल-पी-लिटिल-ए" कहा जाता है, एक एलडीएल जैसी कणिका है जिसके साथ एक अतिरिक्त चिपचिपा प्रोटीन जुड़ा होता है।. — causal drivers of atherosclerosis, with an expanded formal role in the 2026 guideline [41]. None is a validated measure of whether an infarction will be noticed.
• Cognitive impairment and communication barriers — impair both perception and reporting, and complicate history-taking afterwards [4].

6.2 Genuinely mixed evidence

Sex. In ARIC, absolute rates of both recognized and unrecognized infarction were higher in men — silent infarction 5.08 per 1,000 person-years in men versus 2.93 in women — while the unrecognized share of all detected infarctions was relatively greater in women, and the mortality consequences trended worse in women [8]. Framingham likewise found a higher unrecognized proportion in women [7], and registry data show women far more likely to present without chest pain [17]. Rotterdam analyses examined prognosis by sex separately [53]. These findings are compatible: men may sustain more silent infarctions while women’s infarctions may be more likely to go unrecognized when they occur. The evidence does not settle it.

Race and ethnicity. In ARIC, Black participants had a numerically higher unrecognized-infarction incidence than White participants (4.45 versus 3.69 per 1,000 person-years) but the difference was not statistically significant, while White participants had a significantly higher rate of clinically recognized infarction (5.04 versus 3.24, p=0.002) [8]. The second finding is the more interpretable and points toward differential recognition. Rewriting either as a universal biological rule would be unwarranted; symptom interpretation, healthcare access, risk-factor distribution, and statistical uncertainty all contribute.

6.3 Plausible but poorly quantified

High fitness and pain tolerance are often proposed as reasons events go unrecognized in athletes and manual workers. Being fit does not establish absence of atherosclerosis, and tolerating strenuous exercise does not make a new symptom benign. But the quantitative cohorts in this review do not supply an estimate of elevated silent-infarction risk in the highly fit, and assigning one would be unjustified. New unexplained exercise symptoms should be evaluated on their own merits [18,45].

Limited access to healthcare is the clearest instance of the recognition-versus-occurrence problem. Fewer clinical encounters mean fewer opportunities for an event to be diagnosed as it happens, and fewer electrocardiograms in which an old infarction might later be noticed. This almost certainly inflates the measured silent fraction in under-served populations without implying any difference in biology.

7. How serious are silent heart attacks

An infarction is irreversible tissue injury, but its functional consequences vary. A small scar can coexist with preserved pumping function and normal daily activity; a larger one can impair contraction, reduce exercise reserve, and support abnormal electrical circuits. Location, scar burden, इजेक्शन अंशEjection fraction is the percentage of blood the main pumping chamber squeezes out with each beat. A normal value is somewhere around 55 to 70 percent., remaining ischaemia, and coexisting disease matter more clinically than whether the original episode hurt.

7.1 Infarct size and ventricular function

Cardiac MRI studies of unrecognized non-Q-wave infarction in patients with suspected coronary disease found infarcts averaging about 8% of left ventricular mass (SD 7%) with generally preserved ejection fraction, averaging 52% (SD 18%) [15]. Mortality in that cohort was markedly elevated, with an all-cause Hazard ratio का हिंदी में अनुवाद है: **खतरा अनुपात** (या 'हेजर्ड रेशियो')एक हैज़र्ड रेशो (संभाव्यता अनुपात) इस बात की तुलना करता है कि दो समूहों में घटनाएँ कितनी तेज़ी से घटती हैं। 0.75 के अनुपात का मतलब है कि उपचारित समूह में घटनाएँ तीन-चौथाई दर पर हुईं।. of 11.4 (95% CI 2.5–51.1). Those intervals are extraordinarily wide — the study was small — and the finding is directional, not numerical. In patients presenting with signs or symptoms of coronary disease, unrecognized myocardial scar on cardiac MRI was the strongest स्वतंत्र पूर्वानुमानकर्ताA variable that statistically forecasts an outcome—such as mortality—even after accounting for other known risk factors like age, BMI, and cholesterol through multivariable analysis. of major adverse हृदय संबंधी घटनाएंहृदय संबंधी नैदानिक रूप से महत्वपूर्ण घटनाएं—जिनमें मायोकार्डियल इंफार्क्शन, अस्थिर एनजाइना और हृदय संबंधी मृत्यु शामिल हैं—कार्डियोवैस्कुलर परीक्षणों में परिणाम समापन बिंदुओं के रूप में उपयोग की जाती हैं।. among the variables examined [16]. Later work confirmed the prognostic weight of clinically unrecognized myocardial fibrosis [48,49].

7.2 Mortality and the ten-year convergence

The ICELAND MI cohort provides the cleanest comparison, because the same population was characterised by cardiac MRI at baseline and followed prospectively for up to 13.3 years. At 3 years, mortality after unrecognized infarction was indistinguishable from no infarction (3% for both) and lower than after recognized infarction (9%). At 5 years, unrecognized infarction had risen to 13%, above no infarction at 8% but below recognized infarction at 19%. By 10 years, unrecognized and recognized infarction were not statistically different at 49% and 51%, and both far exceeded no infarction at 30% (p<0.001) [10].

Adjusted for age, sex, and diabetes, unrecognized infarction versus no infarction carried hazard ratios of 1.61 (95% CI 1.27–2.04) for death, 1.56 (1.26–1.93) for major adverse cardiac events, 2.09 (1.45–3.03) for subsequent infarction, and 1.52 (1.09–2.14) for हार्ट फेलियरHeart failure means the heart cannot pump well enough to meet the body's needs. The name is misleading — it does not mean the heart has stopped. [10]. Earlier follow-up at 6.4 years had already shown unrecognized infarction by MRI independently associated with mortality (HR 1.45, 95% CI 1.02–2.06) and improving risk stratification, whereas unrecognized infarction defined by ECG did not [9].

The largest synthesis is a मेटा-विश्लेषणएक मेटा-विश्लेषण सांख्यिकीय रूप से कई अलग-अलग अध्ययनों के परिणामों को एक समग्र अनुमान में मिलाता है।. of 30 prospective studies, 253,425 participants, and 1,621,920 person-years. ECG-defined unrecognized infarction was associated with सभी कारणों से होने वाली मृत्यु दरसर्वांगीण मृत्युदर का अर्थ किसी भी कारण से होने वाली मृत्यु है, न कि केवल हृदय रोग से — यह किसी अध्ययन द्वारा मापा जाने वाला सबसे व्यापक और हेरफेर से परे परिणाम है।. HR 1.50 (95% CI 1.30–1.73), cardiovascular mortality 2.33 (1.66–3.27), and major adverse cardiac events 1.61 (1.38–1.89) versus no infarction. MRI-defined estimates were higher — all-cause mortality 3.21 (1.43–7.23), cardiovascular mortality 10.79 (4.09–28.42), major adverse cardiac events 3.23 (2.10–4.95) — but with very wide intervals and significant heterogeneity [12]. Those wide intervals reflect few studies in selected referral populations and do not establish that MRI-detected infarcts are intrinsically more dangerous than ECG-detected ones.

In ARIC, silent infarction versus no infarction carried hazard ratios of 3.06 (95% CI 1.88–4.99) for coronary heart disease death and 1.34 (1.09–1.65) for all-cause mortality, against 4.74 and 1.55 after recognized infarction [8].

7.3 Heart failure and sudden death

For heart failure, ARIC reported incidence of 7.8 per 1,000 person-years with no infarction, 16.2 with silent infarction, and 30.4 with clinically recognized infarction; the adjusted hazard ratio for silent infarction was 1.35 (95% CI 1.02–1.78) against 2.85 (2.31–3.51) for recognized infarction [13].

For sudden cardiac death the ordering reverses. Over a median 25.4 years in ARIC, the multivariable hazard ratio was 5.20 (95% CI 3.81–7.10) after silent infarction and 3.80 (2.76–5.23) after clinically recognized infarction [14]. A plausible reading is that recognized infarction brings beta-blockade, revascularisation, device evaluation, and follow-up, while silent infarction leaves an arrhythmogenic scar in an untreated patient. That is inference from observational data, not a demonstrated mechanism.

Figure 3. Adjusted hazard ratios [8,10,12,13,14,23,25] and absolute 10-year mortality [10]. Association does not establish कारणताकार्यों-कारण का अर्थ है कि एक चीज़ वास्तव में दूसरी चीज़ के होने का कारण बनती है। यह सहसंबंध से अलग है, जिसका अर्थ केवल यह है कि दो चीजें एक साथ दिखाई देती हैं।..

7.4 Biologically less severe, or merely less noticed?

The evidence supports mostly less noticed. Silent infarcts are on average smaller, more often subendocardial and non-Q-wave, and associated with better preserved ejection fraction. If severity were the whole story, prognosis should be correspondingly better — and in the short term it is. What the ten-year data show is that the initial advantage erodes and then disappears [10]. The lesion is smaller; the trajectory converges. The most parsimonious explanation is that the underlying disease continues in both groups but only one is being treated for it.

One selection effect deserves naming. Studies that identify old scars in living volunteers necessarily miss people who died before enrollment. This survivor selection can make imaging cohorts look less acutely severe than the full event population.

8. How serious are silent brain infarctions

A small infarct may spare the pathways needed for obvious speech or limb function while still injuring networks involved in attention, memory, processing speed, or gait. Multiple lesions can be cumulative. At the same time, a single incidental lesion does not establish dementia or explain every later cognitive complaint.

8.1 Prevalence

In the Rotterdam Scan Study, 259 of 1,077 participants aged 60 to 90 (24%) had at least one infarct on MRI, and 217 had silent infarcts only; silent infarcts were roughly five times more prevalent than symptomatic ones [21]. Repeat imaging in the same study found 81 of 668 participants (12.1%) developed new silent infarcts over a mean 3.4 years — a longitudinal observation subject to return-for-scan selection, and not an annual rate [22]. In the Framingham Offspring Study, silent cerebral infarction was present in 10.7% of 2,040 stroke-free participants with mean age 62, scanned between 1999 and 2005 [24]. A व्यवस्थित समीक्षाएक व्यवस्थित समीक्षा (सिस्टमैटिक रिव्यू) पूर्व-घोषित पद्धति का उपयोग करके किसी प्रश्न पर हर अध्ययन की खोज करती है, फिर सुसंगत मानदंडों द्वारा उनका मूल्यांकन करती है।. found published prevalence from 5% to 62%, most studies clustering between 10% and 20%, with annual incidence of 2% to 4% [27]. The AHA/ASA statement summarises prevalence as approximately 25% among people older than 80 [4].

The wide published range reflects population age, MRI field strength and sequence, and lesion definition rather than genuine disagreement about biology.

8.2 Consequences

Cognition and dementia. In 1,015 Rotterdam Scan Study participants aged 60 to 90 and free of stroke and dementia at baseline, 30 developed dementia during a mean 3.6 years. Baseline silent infarction was associated with dementia at HR 2.26 (95% CI 1.09–4.70), and steeper decline in global cognition; the pattern was lesion-dependent, with thalamic infarcts associated with memory decline and non-thalamic infarcts with psychomotor slowing. Decline was concentrated among those who accrued new infarcts [23]. The figure of 30 of 1,015 describes the whole cohort and must not be substituted for absolute dementia risk among those with a silent infarct.

Future clinical stroke. A meta-analysis of 13 studies and 14,764 subjects found a crude सापेक्ष जोखिमसापेक्ष जोखिम दो समूहों की तुलना करता है: इस समूह में उस समूह की तुलना में 30 प्रतिशत कम दिल के दौरे पड़े।. of 2.94 (95% CI 2.24–3.86) and an adjusted hazard ratio of 2.08 (1.69–2.56); in stroke-free cohorts the adjusted hazard was 2.06 (1.64–2.59) among approximately 9,483 people, with silent infarction present in about 18% [25]. This is a doubling of hazard over follow-up, not a statement that half of affected people will have a stroke.

Mortality and other markers. A broader meta-analysis of MRI markers of vascular brain injury associated covert infarcts with subsequent stroke and with all-cause death at HR 1.64 (95% CI 1.40–1.91) [26]. Findings for white matter hyperintensity or microbleeds require their own labels; a strong association for one MRI marker is not the effect size for a silent ischaemic infarct.

Gait and balance disturbance, depressive symptoms, and loss of functional independence are also described in silent cerebrovascular disease [4], though the evidence there is thinner and effect sizes less firmly established. The evidence does not support a single depression probability caused by one incidental infarct.

Table 2. Silent (covert) cerebral infarction

Estimate	Population / period	पद्धति	Value	Limitations
Prevalence, ages 60–90	Rotterdam Scan Study, 1995–1996 MRI [21]	Brain MRI	24% with ≥1 infarct; 217/1,077 (20.1%) with silent infarcts only	Cross-sectional prevalence; no CI supplied for the proportion; single country
Ratio to symptomatic	Rotterdam Scan Study [21]	Brain MRI	Silent ~5× more prevalent than symptomatic	Ratio of prevalences, not of annual events
New silent infarcts	Rotterdam repeat MRI, 1999–2000 [22]	Serial brain MRI	81/668 (12.1%) over mean 3.4 years	Not 12.1% per year; return-for-scan selection applies
Prevalence, mean age 62	Framingham Offspring, MRI 1999–2005 [24]	Brain MRI	10.7% of 2,040 stroke-free participants	Community cohort; CI not quoted; no national extrapolation
Prevalence, age >80	AHA/ASA statement [4]	Brain MRI, pooled summary	~25% with ≥1 silent brain infarct	Age-group summary; no single pooled denominator or CI
Published prevalence range	Systematic review, 2014 [27]	Brain MRI, varied protocols	5% to 62%; most studies 10–20%	Range driven by age, protocol, and lesion definition
Annual incidence	Systematic review, 2014 [27]	Serial brain MRI	2% to 4% per year	Requires repeat imaging; few cohorts have it
Future clinical stroke	Meta-analysis, 13 studies, n=14,764, 2016 [25]	Baseline MRI, clinical follow-up	Crude RR 2.94 (2.24–3.86); adjusted HR 2.08 (1.69–2.56)	Heterogeneous component studies; residual confoundingThe bias that remains in an observational study even after statistical adjustment, because some shared risk factors — such as poverty, smoking, or diabetes — cannot be fully measured or removed; with a modest relative risk like 1.20, residual confounding alone could plausibly explain the entire observed association. by shared जोखिम कारकजोखिम कारक वह है जो आपके किसी बीमारी से पीड़ित होने की संभावना को बढ़ाता है — उच्च कोलेस्ट्रॉल कण, उच्च रक्तचाप, धूम्रपान, मधुमेह, परिवार का इतिहास।.
Dementia	Rotterdam Scan Study, n=1,015 [23]	Brain MRI, prospective follow-up	HR 2.26 (1.09–4.70)	Wide interval; 30 dementia cases in the whole cohort over mean 3.6 years
All-cause death	Meta-analysis of MRI markers, 2019 [26]	Brain MRI	HR 1.64 (1.40–1.91)	Association with vascular injury and underlying disease; not a causal attributable fraction
U.S. annual count	Extrapolation published 2003 [28]	Modeled from age-specific MRI prevalence applied to the 1998 U.S. population	~9 million people with a first silent MRI infarct	MODELED. Converts cross-sectional prevalence into modeled incidence; not measured; not a 2026 figure; silent haemorrhages must be kept separate
Worldwide prevalence	—	—	NOT ESTABLISHED	No representative global imaging data; extrapolation not attempted

Table 3. Outcomes after silent versus recognized events

परिणाम	Silent / unrecognized	Clinically recognized	Reference group	स्रोत
All-cause mortality, 10 y (absolute)	49%	51% (not statistically different)	30%, no MI	ICELAND MI [10]
All-cause mortality (adj. HR)	1.61 (1.27–2.04)	—	No MI = 1.0	ICELAND MI, 10 y [10]
All-cause mortality (adj. HR)	1.34 (1.09–1.65)	1.55	No MI = 1.0	ARIC [8]
All-cause mortality, UMI by ECG (adj. HR)	1.50 (1.30–1.73)	—	No MI = 1.0	Meta-analysis, 30 studies [12]
All-cause mortality, UMI by CMR (adj. HR)	3.21 (1.43–7.23)	—	No MI = 1.0	Meta-analysis [12]
Cardiovascular mortality, UMI by ECG	2.33 (1.66–3.27)	—	No MI = 1.0	Meta-analysis [12]
Cardiovascular mortality, UMI by CMR	10.79 (4.09–28.42)	—	No MI = 1.0	Meta-analysis [12] — very wide interval
Coronary heart disease death (adj. HR)	3.06 (1.88–4.99)	4.74	No MI = 1.0	ARIC [8]
Major adverse cardiac events (adj. HR)	1.56 (1.26–1.93)	—	No MI = 1.0	ICELAND MI, 10 y [10]
Major adverse cardiac events, UMI by ECG	1.61 (1.38–1.89)	—	No MI = 1.0	Meta-analysis [12]
Heart failure (absolute rate)	16.2 per 1,000 py	30.4 per 1,000 py	7.8 per 1,000 py	ARIC [13]
Heart failure (adj. HR)	1.35 (1.02–1.78)	2.85 (2.31–3.51)	No MI = 1.0	ARIC [13]
Heart failure (adj. HR)	1.52 (1.09–2.14)	—	No MI = 1.0	ICELAND MI, 10 y [10]
Subsequent MI (adj. HR)	2.09 (1.45–3.03)	—	No MI = 1.0	ICELAND MI, 10 y [10]
Sudden cardiac death (adj. HR)	5.20 (3.81–7.10)	3.80 (2.76–5.23)	No MI = 1.0	ARIC, median 25.4 y [14]
Future clinical stroke after silent brain infarct	2.08 (1.69–2.56)	—	No silent infarct = 1.0	Meta-analysis [25]
Dementia after silent brain infarct	2.26 (1.09–4.70)	—	No silent infarct = 1.0	Rotterdam Scan Study [23]
All-cause death with covert brain infarcts	1.64 (1.40–1.91)	—	No covert infarct = 1.0	Meta-analysis of MRI markers [26]

All hazard ratios are adjusted, from observational cohorts, with 95% confidence intervals where published. Dashes indicate the comparison was not reported in that source. A hazard ratio is not a cumulative risk ratio. Cardiac and cerebral outcomes are listed separately and are never combined. Missing पूर्ण जोखिमपरम जोखिम इस बात की वास्तविक संभावना है कि आपके साथ कुछ होगा, जिसे प्रतिशत के रूप में लिखा जाता है। यदि अगले दस वर्षों में दिल का दौरा पड़ने का आपका परम जोखिम 12 प्रतिशत है, तो इसका मतलब है कि आप जैसे हर 100 में से लगभग 12 लोगों को यह होगा।. are not created by multiplying hazard ratios by an arbitrary baseline.

9. Short- and long-term aftereffects

9.1 Immediate and structural

Myocardial necrosis is irreversible. Tissue lost during an infarction is replaced by collagenous scar, which does not contract, conducts abnormally, and alters the mechanical loading of surrounding myocardium. In the brain the corresponding lesion is infarcted tissue that may cavitate into a lacune. Acute complications can occur despite minimal outward illness — impaired contraction or arrhythmia in the heart, a focal deficit in the brain.

9.2 Intermediate

Over weeks and months, ventricular remodelling follows as geometry changes in response to altered loading. Remaining myocardium can compensate, but compensation does not erase the injury. Because silent infarcts are on average smaller, remodelling is on average less pronounced — but it is not absent, and it is unmonitored in someone who does not know the infarct occurred. In the brain, rehabilitation and neural adaptation may improve function even though tissue has been lost; the effects of small lesions depend heavily on location and accompanying disease [23].

9.3 Long-term

Reduced cardiac reserve is the intermediate consequence: a heart with scar meets resting demand but has less capacity under stress, which may present as a decline in exercise tolerance attributed to age. Heart failure is the clinical endpoint of that trajectory [13]. Electrical instability arising from scar underlies the elevated sudden-death risk [14]. On the cerebral side, consequences are subtle and cumulative — decrements in memory, attention, processing speed, and executive function, with the pattern depending on lesion location [23] — alongside gait disturbance and loss of independence [4].

9.4 Psychological

An incidental diagnosis carries its own burden: anxiety about what else may be undetected, distress about a body that gave no warning, and difficulty trusting future symptom perception. Clinicians delivering these results should anticipate it. It is also a genuine harm of screening and belongs in the harms column of section 11. Emotional distress after an unexpected scan result deserves attention without assuming the scan predicts imminent decline.

9.5 The consequence that matters most: delayed secondary prevention

The ICELAND MI investigators reported that स्टैटिनएक स्टैटिन उस एंजाइम को धीमा कर देता है जिसका उपयोग आपका यकृत (लिवर) कोलेस्ट्रॉल बनाने के लिए करता है। आपका यकृत आपके रक्त से अधिक कोलेस्ट्रॉल खींचकर प्रतिक्रिया करता है, और यहीं से वास्तविक लाभ मिलता है।. use was less common in participants with unrecognized than with recognized infarction [9]. A population with a demonstrated infarct — one that by any reasonable clinical standard warrants intensive risk-factor treatment — was systematically under-treated because nobody knew. Whatever fraction of the excess long-term risk is attributable to that treatment gap is in principle recoverable.

In principle is doing real work in that sentence. No randomised trial has tested whether treating a screening-detected silent infarction with guideline-directed द्वितीयक रोकथामसेकेंडरी रोकथाम किसी ऐसे व्यक्ति का इलाज करना है जिसे पहले ही दिल का दौरा, स्ट्रोक या स्टेंट लग चुका है, ताकि अगला दौरा रोका जा सके।. improves outcomes, and the observation does not quantify how much later risk would disappear if every silent infarct were detected [10].

10. How silent events are discovered

Modality	What it detects	Limitations
Resting electrocardiogram	Pathological Q waves indicating prior transmural infarction	Insensitive; Q waves may regress; mimics exist. In ARIC, prevalence ranged 0.6%–7.0% by criterion [8]. The Fifth Universal Definition notes limited specificity and recommends imaging confirmation [3]. An automated ‘old infarct’ report needs clinical confirmation
Echocardiography	Regional wall-motion abnormality, ejection fraction, alternative explanations	A normal study cannot exclude every small scar; small subendocardial infarcts may not produce a detectable abnormality
Cardiac troponin	Acute myocyte necrosis; chronically, low-level myocardial injury	Rises and falls, so a normal level long after a suspected episode does not exclude prior infarction; chronic elevation has several causes. High-sensitivity assays are chronic risk markers, not retrospective diagnostics [33,34]
Cardiac MRI with late gadolinium enhancement	Myocardial scar including subendocardial non-Q-wave infarction; subendocardial or transmural pattern in a coronary distribution supports ischaemic injury	Reference standard. Midwall or subepicardial patterns suggest other processes; the ischaemic/non-ischaemic distinction is essential when interpreting a scar count [11]. Cost, availability, gadolinium exposure
कोरोनरी सीटी एंजियोग्राफीकोरोनरी सीटी एंजियोग्राफी, या सीसीटीए, आपकी नसों में डाई के साथ किया जाने वाला एक सीटी स्कैन है जो आपके हृदय की धमनियों की विस्तृत तस्वीरें तैयार करता है।.	Coronary anatomy and प्लाक का बोझप्लाक का बोझ आपकी धमनियों में हर जगह प्लाك की कुल मात्रा है - न कि केवल सबसे खराब जगह पर।.	Depicts disease, not prior infarction; not interchangeable with MRI scar assessment; radiation and iodinated contrast
कोरोनरी धमनीधमनी एक ऐसी रक्त वाहिका है जो हृदय से शरीर के बाकी हिस्सों तक रक्त ले जाती है।. calcium scoring	Calcified plaqueकैल्सीफाइड प्लाक, प्लाक का कठोर, कैल्शियम से भरा हुआ हिस्सा होता है। यह सीटी स्कैन पर चमकता हुआ दिखाई देता है, जिसे कैल्शियम स्कैन मापता है।. burden	Measures plaque, not previous myocardial necrosis. A risk-refinement tool, not a test for past infarction [41]
Brain MRI (FLAIR, DWI)	Covert infarcts; DWI distinguishes acute from chronic; lacunes distinguishable from white matter hyperintensity	Lesion definitions vary across studies and drive much of the published prevalence range; mimics such as enlarged perivascular spaces must be excluded [4,5]
Brain CT	Established, especially larger and cavitated infarcts	Substantially less sensitive than MRI for small covert lesions
Ambulatory rhythm monitoring	Atrial fibrillation and other arrhythmias contributing to cerebral infarction	Identifies a mechanism, not the infarct; yield depends on monitoring duration
Carotid and peripheral vascular imaging	Carotid plaque and स्टेनोसिसस्टेनोसिस का अर्थ है संकीर्णन — आमतौर पर इसे प्रतिशत के रूप में वर्णित किया जाता है, जैसे कि 70 प्रतिशत रुकावट।.; ankle-brachial index for peripheral disease	Identifies atherosclerosis or PAD, not a previous cardiac or cerebral infarction [31,32]
Incidental detection	Findings on imaging performed for other reasons, or in research cohorts	Ascertainment is non-systematic, so incidental case series cannot estimate population prevalence

10.1 Why ECG and cardiac MRI disagree

The most important methodological point in this review is contained in one comparison. In ICELAND MI, the same 936 people were assessed both ways: cardiac MRI found unrecognized infarction in 17%, electrocardiography in 5% [9]. The people did not change. The measurement did.

Electrocardiography detects prior infarction through pathological Q waves, which require sufficient transmural loss of electrically active myocardium. Subendocardial infarction — which much silent infarction turns out to be — frequently produces no Q wave. Cardiac MRI with late gadolinium enhancement images scar directly and resolves very small lesions.

Two consequences follow, pointing in opposite directions. ECG-based studies almost certainly underestimate the true burden of myocardial scarring, so figures derived from them are floors. Conversely, highly sensitive imaging may detect small scars whose ischaemic origin is uncertain, and MESA’s inclusion of non-ischaemic scar patterns illustrates the problem [11]. Neither modality is simply right, and pooling their outputs into a single prevalence estimate is not defensible. ECG-detected and MRI-detected unrecognized infarctions are not the same infarctions.

11. Screening: what helps, what is unproven, what may harm

Four questions that are routinely conflated 1. Does the test detect atherosclerotic risk? For coronary calcium scoringA non-contrast CT scan that quantifies calcified plaque in the coronary arteries and expresses the result as an Agatston score; a score of zero indicates very low near-term risk, while higher scores correlate with greater plaque burden. The article positions it not as a method to detect past silent events but as a tiebreaker when a decision about starting preventive medication is genuinely uncert…, yes. 2. Does it detect obstructive disease or ischaemia? For stress testing and CT angiography, yes. 3. Does it detect a previous silent infarction? For cardiac MRI, yes, better than anything else. 4. Does screening asymptomatic people with it prevent the next clinical event? A separate question, and for most modalities the randomised answer is negative or absent. A test can be excellent at 1, 2, and 3 and still fail 4.

11.1 Randomised evidence

DIAD randomised 1,123 asymptomatic adults with type 2 diabetes to stress मायोकार्डियल पर्फ़्यूजनमायोकार्डियल परफ्यूजन से तात्पर्य हृदय की मांसपेशी तक ऑक्सीजन युक्त रक्त पहुँचाने से है; इसे आहार या औषधिय हस्तक्षेपों ने पहले से कम रक्त आपूर्ति वाले हृदय ऊतक में रक्त प्रवाह में सुधार किया है या नहीं, इसका आकलन करने के लिए पीईटी इमेजिंग से मापा जा सकता है।. screening or no screening. Over approximately five years, cardiac death or nonfatal infarction occurred in 2.7% versus 3.0% (HR 0.88, 95% CI 0.44–1.8). The trial did not demonstrate benefit, though the wide interval means absence of significance is not proof of identical effects. Roughly 22% had abnormal scans, but these included perfusion and non-perfusion findings and should not all be called silent infarction or even the same form of silent ischaemia [35].

FACTOR-64 randomised 900 asymptomatic patients with diabetes to coronary CT angiography screening or usual care. The primary outcome occurred in 6.2% versus 7.6% over about four years (HR 0.80, 95% CI 0.49–1.32), without significant reduction [36]. This does not settle every modern CT strategy, but it prevents any claim that CT screening has been proved to improve outcomes.

DANCAVAS invited 46,611 Danish men aged 65 to 74 to comprehensive cardiovascular screening. All-cause mortality was not significantly reduced (HR 0.95, 95% CI 0.90–1.00, p=0.06), with a pre-specified subgroup aged 65 to 69 suggesting benefit (HR 0.89) [37].

No randomised trial has evaluated screening asymptomatic adults with cardiac MRI for silent infarction, or with brain MRI for covert infarction, using clinical events as the endpoint. This is the central evidence gap in the field.

11.2 Guideline positions

The USPSTF recommends against screening with resting or exercise electrocardiography in asymptomatic adults at low cardiovascular risk (ग्रेडग्रेड (GRADE - Grading of Recommendations, Assessment, Development and Evaluations) नैदानिक निष्कर्ष के पीछे के साक्ष्य की निश्चितता का मूल्यांकन करने के लिए व्यापक रूप से इस्तेमाल किया जाने वाला एक ढांचा है, जो अध्ययन के डिज़ाइन, पूर्वाग्रह के जोखिम, स्थिरता, प्रत्यक्षता और परिणामों की सटीकता जैसे कारकों के आधार पर इसे उच्च, मध्यम, कम या बहुत कम के रूप में वर्गीकृत करता है।. D), and finds evidence insufficient at intermediate or high risk (I statement) [38]. It recommends against screening for asymptomatic करोटिड धमनीThe carotid arteries run up either side of your neck and supply blood to your brain. stenosis (grade D) [39], and finds evidence insufficient for ankle-brachial index screening in asymptomatic adults (I statement) [40]. None of this is a recommendation to ignore an abnormal ECG or a new symptom.

Coronary artery calcium occupies a narrower, guideline-supported role: refining risk when a preventive treatment decision remains uncertain. The 2026 डिस्लिपिडिमियाडyslipidemia रक्त में वसा के एक अस्वस्थ पैटर्न के लिए चिकित्सीय शब्द है। इसका मतलब उच्च एलडीएल (LDL), उच्च ट्राइग्लिसराइड्स, कम एचडीएल (HDL), या इनका कोई संयोजन हो सकता है।. guideline adopts a calculate–personalise–reclassify approach, estimating ten-year risk with the समीकरणों को रोकेंPREVENT (कार्डियोवैस्कुलर डिसीज़ इवेंट्स के जोखिम का अनुमान) समीकरण 2026 ACC/AHA दिशानिर्देशों में अपनाया गया एक हृदय संबंधी जोखिम मॉडल है जो ASCVD के 10-वर्षीय और 30-वर्षीय दोनों आजीवन जोखिम का अनुमान लगाता है, जो पुराने फ़्रेमिंगहैम-आधारित पूल्ड कोहॉर्ट समीकरणों की जगह लेता है और 30 वर्ष की आयु से शुरू होने वाले शुरुआती जोखिम स्तरीकरण को सक्षम बनाता है।. and using coronary calcium selectively to reclassify [41]. Crucially it can move a person either way; a score of zero can support deferral. Multimodality appropriate-use guidance permits selected testing in patients at high risk of silent ischaemia [45], and in stable chronic coronary disease routine periodic testing without a change in clinical or functional status is not recommended [43].

11.3 Harms

• False positives, leading to further testing that carries its own risk.
• Incidental findings — pulmonary nodules on cardiac CT, aneurysms or tumours on brain MRI — triggering cascades of uncertain benefit.
• Ionising radiation from CT and nuclear testing; iodinated contrast; gadolinium exposure with cardiac MRI, with kidney function to consider.
• Unnecessary invasive testing, including angiography prompted by abnormalities that would never have caused events.
• Overtreatment, including bleeding risk from preventive antithrombotic therapy started on the strength of a screening finding.
• Anxiety and the burden of being labelled (section 9.4).
• Cost, with opportunity cost for interventions of proven benefit.

These trade-offs differ by test and should not be collapsed into a generic warning about all imaging.

11.4 Where individualised evaluation may be reasonable

Nothing here supports advanced imaging for all asymptomatic adults, and no major guideline body recommends it. Individualised evaluation through साझा निर्णय-निर्माणसाझा निर्णय-निर्माण एक ऐसा नैदानिक ​​दृष्टिकोण है जिसमें चिकित्सक और रोगी दोनों मिलकर उपलब्ध साक्ष्यों—जिसमें इमेजिंग परिणाम, जोखिम कारक और व्यक्तिगत लक्ष्य शामिल हैं—पर विचार करते हैं ताकि एक ऐसा प्रबंधन विकल्प तैयार किया जा सके जो चिकित्सा की सर्वोत्तम प्रथा और व्यक्ति के मूल्यों दोनों को दर्शाता हो; 2025 के AHA/ACC दिशानिर्देश विशेष रूप से उन एथलीटों के लिए इसका आह्वान करते हैं जिनमें बढ़े हुए कोरोनरी कैल्शियम स्कोर पाए जाते हैं।. may nonetheless be reasonable when a statin decision is genuinely balanced at intermediate estimated risk; in diabetes or chronic गुर्दे की बीमारीKidney disease means the kidneys have lost some of their ability to filter waste from your blood., where risk is elevated and symptom perception may be unreliable; with a strong पारिवारिक इतिहासपारिवारिक इतिहास का मतलब यह है कि क्या आपके करीबी रिश्तेदारों को हृदय रोग हुआ था, और जब यह हुआ तब वे कितने कम उम्र के थे।. of premature ASCVD; with markedly abnormal lipid parameters including elevated लाइपोप्रोटीनलाइपोप्रोटीन एक छोटा पैकेट है जो आपके रक्तप्रवाह के माध्यम से वसा और कोलेस्ट्रॉल ले जाता है। चूंकि वसा पानी में नहीं घुलती है, इसलिए इसे यात्रा करने के लिए एक प्रोटीन आवरण की आवश्यकता होती है।.(a) or apolipoprotein B; or when an abnormal examination, ECG, functional change, or embolic imaging pattern raises a sufficiently specific clinical question [41,45]. The purpose is to sharpen a treatment decision, not to search for disease for its own sake.

12. Prevention and clinical implications

An incidental finding should first be confirmed and classified. The next questions are what caused it, whether symptoms were missed, whether cardiac or cerebral function is affected, and which preventive measures would change outcomes.

12.1 A confirmed previous coronary infarction

The 2018 Multisociety कोलेस्ट्रॉलकोलेस्ट्रॉल एक मोमी पदार्थ है जिसकी आपके शरीर को आवश्यकता होती है। यह कोशिका की दीवारों, हार्मोनों, विटामिन डी और आपके भोजन को पचाने वाले पित्त में जाता है। इसके बिना आपकी मृत्यु हो जाएगी।. Guideline defined clinical ASCVD to include acute coronary syndromes, history of myocardial infarction, stable or अस्थिर एनजाइनाअस्थिर एनजाइना (अन्स्टेबल एनजाइना) छाती की वह बेचैनी है जो आराम करते समय होती है, पहले की तुलना में कम मेहनत करने पर होती है, या अचानक बदतर हो रही होती है।., coronary or other arterial revascularisation, stroke, transient ischaemic attack, and peripheral arterial disease of atherosclerotic origin [42]. That guideline has been retired and replaced by the 2026 ACC/AHA Multisociety Dyslipidemia GuidelineA joint clinical practice guideline from the American Heart Association and American College of Cardiology that, among other recommendations, tabulates estimated ASCVD relative-risk increments at Lp(a) concentrations from 50 to 180 mg/dL, derived from UK Biobank modeling., which is more granular than a binary primary-versus-secondary split [41]:

• Clinical ASCVD at very high risk: LDL-C goal below 55 mg/dL. Very high risk means multiple major ASCVD events — acute coronary syndrome within 12 months, prior myocardial infarction other than that, prior ischaemic stroke, or symptomatic peripheral arterial disease — or one major event plus multiple high-risk conditions such as age over 65, prior revascularisation, current smoking, diabetes, heart failure, hypertension, or LDL-C above 100 mg/dL despite maximally tolerated statin plus एज़ेटिमाइबएज़ेटिमाइब एक ऐसी गोली है जो आपकी आंतों को कोलेस्ट्रॉल को अवशोषित करने से रोकती है।..
• Clinical ASCVD not at very high risk: goal below 70 mg/dL.
• प्राथमिक रोकथामप्राथमिक रोकथाम किसी ऐसे व्यक्ति का इलाज करना है जिसे कभी दिल का दौरा या स्ट्रोक नहीं हुआ है, ताकि पहले को होने से रोका जा सके।.: below 70 mg/dL for heterozygous familial hypercholesterolaemia, one or more ASCVD risk factors, or सबक्लिनिकल एथरोस्क्लेरोसिसSubclinical atherosclerosis means plaque is present but has not yet caused any symptoms or events.. Calcium-stratified goals are also specified — below 100 mg/dL for scores of 1 to 99 एगैटस्टन यूनिट्सAgatston units are the standardized scoring units used to quantify coronary artery calcium on a CT scan, calculated from the density and area of calcified lesions; a score of zero indicates no detectable calcified plaque, while scores of 300 or above — found exclusively in the athlete group in the UK Masters study — reflect heavy calcification. and below the 75th percentile for age, sex, or race; below 70 mg/dL for 100 to 299 or at or above the 75th percentile; below 55 mg/dL for scores at or above 1,000.

So objectively documenting a prior silent myocardial infarction places a person in the clinical ASCVD category, and prior myocardial infarction is explicitly among the major events defining very high risk. Beyond lipid targets, this brings antiplatelet decisions based on ischaemic and bleeding risk, blood-pressure and glycaemic control, smoking cessation, physical activity and rehabilitation where appropriate, evaluation of left ventricular function, and structured follow-up [43]. An ECG suggestion alone, or a non-ischaemic scar pattern, does not establish the same diagnosis.

12.2 An incidental silent brain infarct — a genuine difference

It is not accurate to assume that every covert brain infarct automatically demands the standard secondary-stroke antiplatelet regimen. The AHA/ASA statement recommends primary-prevention principles in this setting, with evaluation directed by lesion pattern and risk factors [4]. The European Stroke Organisation guideline specifically advises against ऐस्पिरिनएस्पिरिन रक्त की पट्टिकाओं (प्लेटलेट्स) को कम चिपचिपा बनाती है, जिससे थक्के बनने की संभावना कम हो जाती है।. for covert cerebral small-vessel disease in the absence of another indication [5]. Atrial fibrillation or another established condition may create a separate indication. Broader primary stroke prevention guidance applies [44].

This is a real asymmetry between the cardiac and cerebral cases, and collapsing the two — as several popular accounts do — would produce a treatment recommendation the evidence does not support.

The honest limit of the पुनर्वर्गीकरणIn cardiovascular risk assessment, reclassification refers to the process by which an additional test — such as a CAC scan or ApoB measurement — moves a patient from one risk category to another, prompting a change in treatment decisions that a standard risk calculator alone would not have triggered. argument Guidelines define who should be treated based on the totality of evidence about risk. They do not demonstrate that a screening-detected silent infarction treated as clinical ASCVD yields the same benefit that treatment yields after a recognized infarction. That trial has not been run. The argument rests on the premise that a myocardial scar carries the same prognostic weight regardless of whether anyone noticed it forming — supported by the outcome data in section 7, but not by randomised evidence of treatment benefit in this specific population.

The shared priorities across both cases are sustained control of vascular risk and a plan for new symptoms. Healthy dietary patterns, regular activity, smoking cessation, hypertension treatment, diabetes management, and appropriate lipid therapy have a stronger clinical foundation than repeated scanning in search of silent injury. Prevention cannot guarantee that an event will never occur, but feeling well is not a reason to leave established risk untreated.

Figure 4. Conceptual pathway. Arrows show possibilities, not obligatory stages, time intervals, or quantified transition probabilities. Cerebral infarction also has embolic and small-vessel pathways not shown [2,4,5,19,43].

13. Evidence gaps and uncertainties

• No randomised trial has tested whether guideline-directed secondary prevention delivers the same benefit after a silent infarction as after a recognized one.
• No randomised trial has tested stroke prevention specifically in people with covert brain infarcts.
• The contemporary annual U.S. and worldwide incidence of imaging-confirmed silent infarction is unknown.
• The proportion of unrecognized infarctions that are genuinely symptom-free has been measured directly only in Framingham, in a different diagnostic era [6]. No contemporary equivalent exists.
• The fraction of covert brain infarcts specifically attributable to atherosclerosis, as opposed to embolic or small-vessel mechanisms, is not established [4,5].
• The clinical significance of very small subendocardial scars detected by high-sensitivity cardiac MRI is incompletely defined, including what fraction are ischaemic in origin [11].
• Disentangling higher event rates from lower diagnosis rates across sex, race, and healthcare-access strata remains unresolved, and is a question about health systems as much as biology [8].
• Age-stratified prevalence is not reported comparably across cohorts, which is why Figure 2 presents study-level ranges rather than a smooth age curve. Neither the figures nor the tables are a personal risk calculatorA risk calculator estimates your chance of a heart attack or stroke over the next ten years, using your age, cholesterol, blood pressure, and a few other inputs..
• Differences in detection can be larger than differences between populations. ECG surveys miss infarcts MRI detects; MRI studies differ in thresholds, sequences, and eligibility; screening volunteers differ from those who cannot participate; older cohorts reflect earlier treatment eras [8,9,11,12,24].

This is a focused narrative evidence review, not a registered systematic review with exhaustive duplicate screening. Publication dates and underlying data years are distinguished throughout. Confidence intervals are reported where available and are not invented where unavailable.

14. Warning signs requiring urgent evaluation

Call 911 in the United States, or the local emergency number elsewhere New chest pressure, tightness, heaviness, or discomfort, which may radiate to the arm, jaw, neck, back, or shoulder — especially with breathlessness, sweating, nausea, or faintness. Shortness of breath that is new, unexplained, or disproportionate to activity, with or without chest discomfort. New severe unexplained fatigue, or a sudden fall in exercise tolerance. Light-headedness, near-fainting, or fainting. Sudden one-sided weakness or numbness, facial droop, difficulty speaking or understanding speech, visual loss, or a new severe balance disturbance — even if it resolves. Note the last time the person was known to be well. A person who is unresponsive and not breathing normally needs an emergency call, CPR, and an AED as soon as one is available.

Do not wait for severe pain, and do not drive yourself when a heart attack is suspected. A brief improvement does not establish that the problem is over: a deficit that clears in twenty minutes may have been a transient ischaemic attack, and a resolving episode of chest discomfort may be unstable angina. The absence of chest pain does not rule out a heart attack — roughly a third of confirmed infarctions present without it, with a higher proportion in women, older adults, and people with diabetes [17].

This review is educational and is not a substitute for individual medical advice.

15. Conclusion

How much of the total ASCVD burden occurs silently? A substantial share, and the honest answer must name the ascertainment method before giving a number. By cardiac MRI in older adults, unrecognized infarctions outnumbered recognized ones roughly two to one in ICELAND MI [9]. By serial electrocardiography, silent infarction accounted for 45.1% of detected incident events in ARIC [8] and more than a quarter in Framingham [6]. By a single resting electrocardiogram, the figure falls to a small percentage. In the brain, covert infarcts outnumber diagnosed strokes several-fold in community-dwelling older adults [21]. There is no single correct number, and any source offering one without naming its modality should be treated with suspicion.

How much is genuinely symptom-free rather than merely unrecognized? Less than the word silent suggests. The one cohort that measured the split directly found that roughly half of unrecognized infarctions were truly silent and the rest caused atypical symptoms [6] — which, applied to that cohort’s own unrecognized share, puts genuinely symptom-free events at something near one in eight of all infarctions there. Modern presentation data point the same way from a different direction: 35.4% of confirmed infarctions arrive without chest pain, yet those patients still sought care because something felt wrong [17]. The dominant mechanism by which a real event becomes a silent one is not the absence of sensation but the misattribution of it.

What does a silent event mean for a person’s future health? That a piece of heart or brain has died, that a scar is present, and that the disease which produced it is still there. In ICELAND MI, ten-year mortality after unrecognized infarction reached 49% against 51% after recognized infarction and 30% with no infarction [10]. A meta-analysis of 30 studies found consistently adverse prognosis [12]. In ARIC, silent infarction carried a fivefold adjusted hazard of sudden cardiac death — higher than after recognized infarction [14]. Covert brain infarcts roughly double the risk of future stroke and of dementia [23,25]. Whatever advantage a smaller infarct confers early is largely spent by ten years.

The most actionable conclusion is also the least comfortable. Part of the danger of a silent event lies in the event, and part lies in the silence. People with unrecognized infarction have been shown to be less likely to receive the medications that protect people with recognized infarction [9]. The lesion was smaller; the treatment was absent. That is a gap clinical recognition can close, and it is why finding an old silent infarction should prompt not reassurance but a shift into secondary-prevention care — while an incidental covert brain infarct warrants a more cautious, cause-directed response rather than the same reflex [4,5].

None of this translates into a recommendation that asymptomatic adults seek advanced imaging. The randomised evidence is negative or absent, the harms are real, and no guideline body endorses it. It translates into two more modest propositions: that the overlooked presentations in section 5 deserve to be as widely known as the classic ones, and that when a silent infarction is found — by whatever route — it should be treated as what it is.

16. References

Vancouver style, numbered in order of first appearance in Part Two. All entries are peer-reviewed journal publications. Entries marked [abstract] were verified against the published abstract because full text was not accessible; entries marked [carried] were carried from a source document with bibliographic details confirmed, but with the specific figures not independently re-verified — these are itemised in the companion Source Verification and Gap Analysis.

1. Martin SS, Aday AW, Allen NB, et al. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2025;151(8):e41–e660. PMID: 39866113.
2. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618–e651. doi:10.1161/CIR.0000000000000617.
3. Joint ESC/ACC/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Fifth Universal Definition of Myocardial Infarction (2026). Circulation. 2026. doi:10.1161/CIR.0000000000001477.
4. Smith EE, Saposnik G, Biessels GJ, et al. Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement From the American Heart Association/American Stroke Association. Stroke. 2017;48(2):e44–e71. doi:10.1161/STR.0000000000000116.
5. Wardlaw JM, Debette S, Jokinen H, et al. ESO Guideline on covert cerebral small vessel disease. Eur Stroke J. 2021;6(2):CXI–CLXII. doi:10.1177/23969873211012132. [carried]
6. Kannel WB, Abbott RD. Incidence and prognosis of unrecognized myocardial infarction: an update on the Framingham Study. N Engl J Med. 1984;311(18):1144–1147. doi:10.1056/NEJM198411013111802. PMID: 6482932. [abstract]
7. Kannel WB. Silent myocardial ischemia and infarction: insights from the Framingham Study. Cardiol Clin. 1986;4(4):583–591. PMID: 3779719. [abstract]
8. Zhang ZM, Rautaharju PM, Prineas RJ, et al. Race and sex differences in the incidence and prognostic significance of silent myocardial infarction in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2016;133(22):2141–2148. PMID: 27185168. [abstract]
9. Schelbert EB, Cao JJ, Sigurdsson S, et al. Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults. JAMA. 2012;308(9):890–896. doi:10.1001/2012.jama.11089. PMID: 22948699.
10. Acharya T, Aspelund T, Jonasson TF, et al. Association of unrecognized myocardial infarction with long-term outcomes in community-dwelling older adults: the ICELAND MI study. JAMA Cardiol. 2018;3(11):1101–1106. doi:10.1001/jamacardio.2018.3285. PMID: 30304454. [abstract]
11. Turkbey EB, Nacif MS, Guo M, et al. Prevalence and correlates of myocardial scar in a US cohort. JAMA. 2015;314(18):1945–1954. doi:10.1001/jama.2015.14849. [carried]
12. Yang Y, Li W, Zhu H, et al. Prognosis of unrecognised myocardial infarction determined by electrocardiography or cardiac magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2020;369:m1184. doi:10.1136/bmj.m1184. PMID: 32381490.
13. Qureshi WT, Zhang ZM, Chang PP, et al. Silent myocardial infarction and long-term risk of heart failure: the ARIC Study. J Am Coll Cardiol. 2018;71(1):1–8. doi:10.1016/j.jacc.2017.10.071. PMID: 29301615.
14. Zhang ZM, Rautaharju PM, Prineas RJ, et al. Association between silent myocardial infarction and long-term risk of sudden cardiac death. J Am Heart Assoc. 2020;9(9):e017044. doi:10.1161/JAHA.120.017044.
15. Kim HW, Klem I, Shah DJ, et al. Unrecognized non-Q-wave myocardial infarction: prevalence and prognostic significance in patients with suspected coronary disease. PLoS Med. 2009;6(4):e1000057. doi:10.1371/journal.pmed.1000057.
16. Kwong RY, Chan AK, Brown KA, et al. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease. Circulation. 2006;113(23):2733–2743. doi:10.1161/CIRCULATIONAHA.105.570648.
17. Canto JG, Rogers WJ, Goldberg RJ, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA. 2012;307(8):813–822. doi:10.1001/jama.2012.199. PMID: 22357832.
18. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. Circulation. 2021. doi:10.1161/CIR.0000000000001029. [carried]
19. Vähätalo JH, Huikuri HV, Holmström LTA, et al. Association of silent myocardial infarction and sudden cardiac death. JAMA Cardiol. 2019;4(8):796–802. doi:10.1001/jamacardio.2019.2210. PMID: 31290935.
20. Marijon E, Uy-Evanado A, Dumas F, et al. Warning symptoms are associated with survival from sudden cardiac arrest. Ann Intern Med. 2016;164(1):23–29. doi:10.7326/M14-2342. [carried]
21. Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MMB. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2002;33(1):21–25. doi:10.1161/hs0102.101629. PMID: 11779883.
22. Vermeer SE, den Heijer T, Koudstaal PJ, et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2003;34(2):392–396. [carried]
23. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215–1222. doi:10.1056/NEJMoa022066. PMID: 12660385.
24. Das RR, Seshadri S, Beiser AS, et al. Prevalence and correlates of silent cerebral infarcts in the Framingham Offspring Study. Stroke. 2008;39(11):2929–2935. doi:10.1161/STROKEAHA.108.516575. [carried]
25. Gupta A, Giambrone AE, Gialdini G, et al. Silent brain infarction and risk of future stroke: a systematic review and meta-analysis. Stroke. 2016;47(3):719–725. doi:10.1161/STROKEAHA.115.011889. PMID: 26888534.
26. Debette S, Schilling S, Duperron MG, Larsson SC, Markus HS. Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis. JAMA Neurol. 2019;76(1):81–94. doi:10.1001/jamaneurol.2018.3122. [carried]
27. Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. BMC Med. 2014;12:119. doi:10.1186/s12916-014-0119-0.
28. Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis. 2003;16(3):280–285. doi:10.1159/000071128. [abstract] MODELED ESTIMATE — see Table 2 limitations.
29. GBD 2021 Stroke Risk Factor Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(10):973–1003. [carried]
30. Bergström G, Persson M, Adiels M, et al. Prevalence of subclinical coronary artery atherosclerosis in the general population. Circulation. 2021;144(12):916–929. doi:10.1161/CIRCULATIONAHA.121.055340. [carried]
31. Gornik HL, Aronow HD, Goodney PP, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease. J Am Coll Cardiol. 2024. [carried]
32. Song P, Fang Z, Wang H, et al. Global and regional prevalence, burden, and risk factors for carotid atherosclerosis: a systematic review, meta-analysis, and modelling study. Lancet Glob Health. 2020;8(5):e721–e729. [abstract]
33. Blankenberg S, Zeller T, et al. Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium. Eur Heart J. 2016;37(30):2428–2437. PMID: 27174290.
34. Willeit P, Welsh P, Evans JDW, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. J Am Coll Cardiol. 2017;70(5):558–568. doi:10.1016/j.jacc.2017.05.062.
35. Young LH, Wackers FJT, Chyun DA, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study, a randomized controlled trial. JAMA. 2009;301(15):1547–1555. doi:10.1001/jama.2009.476. [abstract]
36. Muhlestein JB, Lappé DL, Lima JAC, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA. 2014;312(21):2234–2243. doi:10.1001/jama.2014.15825. [carried]
37. Lindholt JS, Søgaard R, Rasmussen LM, et al. Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) trial. N Engl J Med. 2022;387(15):1385–1394. PMID: 36027560. [abstract]
38. US Preventive Services Task Force. Screening for cardiovascular disease risk with electrocardiography: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(22):2308–2314. [abstract]
39. US Preventive Services Task Force. Screening for asymptomatic carotid artery stenosis: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(5):476–481. [abstract]
40. US Preventive Services Task Force. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(2):177–183. [abstract]
41. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026;87(19):2624–2757. PMID: 41824590. Also Circulation, doi:10.1161/CIR.0000000000001423.
42. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082–e1143. doi:10.1161/CIR.0000000000000625. RETIRED and replaced by ref 41; cited for the historical definition of clinical ASCVD.
43. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/Multisociety Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023. doi:10.1161/CIR.0000000000001168. [carried]
44. Bushnell C, Kernan WN, Sharrief AZ, et al. 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2024. doi:10.1161/STR.0000000000000475. [carried]
45. Winchester DE, Maron DJ, Blankstein R, et al. 2023 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Chronic Coronary Disease. J Am Coll Cardiol. 2023. [carried]
46. Sheifer SE, Gersh BJ, Yanez ND 3rd, et al. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. J Am Coll Cardiol. 2000;35(1):119–126. [carried]
47. Boland LL, Folsom AR, Sorlie PD, et al. Occurrence of unrecognized myocardial infarction in subjects aged 45 to 65 years (the ARIC study). Am J Cardiol. 2002;90(9):927–931. [carried]
48. Nordenskjöld AM, Hammar P, Ahlström H, et al. Unrecognized myocardial infarction assessed by cardiac magnetic resonance imaging — prognostic implications. PLoS One. 2016;11(2):e0148803. doi:10.1371/journal.pone.0148803. [carried]
49. Antiochos P, Ge Y, Steel K, et al. Imaging of clinically unrecognized myocardial fibrosis in patients with suspected coronary artery disease. J Am Coll Cardiol. 2020;76(8):945–957. doi:10.1016/j.jacc.2020.06.063. [carried]
50. Barbier CE, Bjerner T, Johansson L, Lind L, Ahlström H. Prevalence of unrecognized myocardial infarction detected with magnetic resonance imaging and its relationship to cerebral ischemic lesions in both sexes. J Am Coll Cardiol. 2011;58(13):1372–1377. [carried]
51. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–1345. [abstract]
52. Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020–e1030. [abstract]
53. Dehghan A, Leening MJG, Solouki AM, et al. Comparison of prognosis in unrecognized versus recognized myocardial infarction in men versus women >55 years of age (from the Rotterdam Study). Am J Cardiol. 2014;113(1):1–6. doi:10.1016/j.amjcard.2013.09.005. [carried]
54. Davis TME, Coleman RL, Holman RR; UKPDS Group. Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: UKPDS 79. Circulation. 2013;127(9):980–987. doi:10.1161/CIRCULATIONAHA.112.000908. [carried]

Disclosure and scope. This review is educational. It is not individual medical advice and does not establish a clinician–patient relationship. Numerical values are reproduced as published; where a confidence interval was not reported in the source, none has been constructed. Observational hazard ratios describe association and do not establish causation.